Emergent BioSolutions (EBS) PT Raised to $112 at Wells Fargo
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- S&P 500 set for muted open after big bank earnings, chip slide weighs
- Oil eases as traders monitor Russian diesel deal, Saudi attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $6.98 --0%
Rating Summary:
12 Buy, 5 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 16 | New: 33
Rating Summary:
12 Buy, 5 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 16 | New: 33
Join SI Premium – FREE
Wells Fargo analyst David Maris raised the price target on Emergent BioSolutions (NYSE: EBS) to $112.00 (from $110.00) while maintaining a Equal Weight rating.
You May Also Be Interested In
- Huber Research double downgrades Netflix to underweight, sets $70 price target
- Myriad Genetics (MYGN) PT Raised to $4.50 at TD Cowen
- Semtech Corp. (SMTC) PT Raised to $230 at BMO Capital
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
